Free Trial

Eliem Therapeutics Q4 2022 Earnings Report

Eliem Therapeutics logo
$2.34 -0.08 (-3.31%)
(As of 12/17/2024 ET)

Eliem Therapeutics EPS Results

Actual EPS
-$0.29
Consensus EPS
-$0.44
Beat/Miss
Beat by +$0.15
One Year Ago EPS
N/A

Eliem Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eliem Therapeutics Announcement Details

Quarter
Q4 2022
Time
N/A
DeFi Coin on Verge of Breakout! (Ad)

The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years.

Claim your FREE book now before it's too late!

Eliem Therapeutics Earnings Headlines

Trump’s Secret Manhattan Project
On January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just spent six months investigating this...and what I found is shocking.
See More Eliem Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eliem Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eliem Therapeutics and other key companies, straight to your email.

About Eliem Therapeutics

Eliem Therapeutics (NASDAQ:ELYM), a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

View Eliem Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings